Phenytoin penetration into brain after administration of phenytoin or fosphenytoin

Epilepsia

Volumn 40, Issue 2, 1999, Pages 153-156

  Walton, Nancy Y ^a   Uthman, Basim M ^b   El Yafi, Karim ^a   Kim, Jae Moon ^c   Treiman, David M ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c Chungnam National University College of Medicine   (South Korea)

^d ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Brain; Fosphenytoin; Phenytoin; Protein binding; Rats

Indexed keywords

FOSPHENYTOIN SODIUM; PHENYTOIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; DRUG BRAIN LEVEL; DRUG FORMULATION; DRUG PENETRATION; EPILEPSY; EPILEPTIC STATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ULTRAFILTRATION;

ANIMALS; ANTICONVULSANTS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN CHEMISTRY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMORAL VEIN; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; PHENYTOIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032923881     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb02068.x     Document Type: Article

References (15)

1. Louis S, Kutt H, McDowell F. The circulatory changes caused by intravenous Dilantin and its solvent. Am Heart J 1967;74:523-9.
2. Stella V, Higuchi T. Esters of hydantoic acid as prodrugs of hydantoins. J Pharm Sci 1973;62:962.
3. Ramsay RE, DeToledo J. Intravenous administration of fosphenytoin: options for the management of seizures. Neurology 1996; 46(suppl 1):S17-9.
4. Browne TR. Fosphenytoin (Cerebyx). Clin Neuropharmacol 1997; 20:1-12.
5. Walton NY, Treiman DM. Efficacy of ACC-9653 (a phenytoin prodrug) in experimental status epilepticus in the rat. Epilepsy Res 1990;5:165-8.
6. Allen FW, Runge JW, Legarda S, et al. Safety, tolerance, and pharmacokinetics of intravenous fosphenytoin (Cerebyx) in status epilepticus. Epilepsia 1995;36(suppl 4):90.
7. Fischer JH, Allen FH, Runge J, et al. Fosphenytoin (Cerebyx) in status epilepticus: safety, tolerance, and pharmacokinetics. Epilepsia 1996;37(suppl 5):202.
8. Lai CM, Moore P, Quon CY. Binding of phosphenytoin, phosphate ester prodrug of phenytoin, to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phenylbutazone, phenytoin, valproic acid or warfarin. Res Commun Mol Pathol Pharmacol 1995;88:51-62.
9. Cwik MJ, Liang M, Deyo K, Andrews C, Fishcher J. Simultaneous high-performance liquid chromatographic determination of phenytoin and its prodrug, fosphenytoin, in human plasma and ultrafiltrate. J Chromatogr B Biomed Appl 1997;693:777-91.
10. Koch-Weser J, Sellers EM. Binding of drugs to serum albumin. N Engl J Med 1976;294:311-6.
11. Cornford EM, Pardridge WM, Braun LD, Oldendorf WH. In-creased blood-brain barrier transport of protein-bound anticonvulsant drugs in the newborn. J Cerebr Blood Flow Metab 1983;3: 280-6.
12. Pardridge WM, Landaw EM, Tracer kinetic model of blood-brain barrier transport of plasma protein-bound ligands: empiric testing of the free hormone hypothesis. J Clin Invest 1984;74:745-52.
13. Greig NH, Brossi A, Pei X-F, Ingram DK, Soncrant TT. Designing drugs for optimal nervous system activity. In: Greenwood J, Begley DJ, Segal MB, eds. New concepts of a blood-brain barrier. New York: Plenum, 1992:251-64.
14. Fenstermacher JD. Pharmacology of the blood-brain barrier. In: Neuwelt EA, ed. Implications of the blood-brain barrier and its manipulation. Vol. I. Basic science aspects. New York: Plenum, 1989:137-55.
15. Ramsay RE, Hammond EJ, Perchalski RJ, Wilder BJ. Brain uptake of phenytoin, phenobarbital, and diazepam. Arch Neurol 1979;36: 535-9.